Cytomyx licenses cancer database to AZ
Clinomics Biosciences, who were acquired by Cytomyx Holdings' in December 2003, has licensed its oncology cell signalling database to AstraZeneca.
Clinomics Biosciences, who were acquired by Cytomyx Holdings' in December 2003, has licensed its oncology cell signalling database to AstraZeneca.
Clinomics' database is based on a unique set of more than 30,000 human oncology samples, representing virtually all forms of cancer. The database was created from Clinomics' broad collection of more than 200,000 highly characterised human samples, which form the basis for new genomic tools to assist the pharmaceutical industry in the discovery of new drugs.
Mike Kerins, Cytomyx's chief executive, said: 'We are delighted that AstraZeneca has chosen our oncology cell signalling database to assist in its cancer drug discovery and the agreement marks a highly significant step following the Clinomics acquisition.
'Clinomics' technology enables us to offer critical new tools to pharmaceutical companies to allow the biological characterisation of gene and protein targets across many disease areas.'
Under the terms of the non-exclusive purchase agreement, AstraZeneca has received multiple user licences to the database along with rights to upgrades.
Dr Patrick Muraca, Clinomics Biosciences' cso, said: 'We have analysed the protein expression patterns of 100 cell signalling proteins across all of the 30,000 oncology samples and integrated this information into a new searchable database. Researchers are able to interrogate a wide range of data fields within the database including patient demographics, medical history, pathology and treatment outcomes to identify factors important in disease progression.'